Call Us: 1.800.873.5297

By

TVM Update: $5.7 Million Jury Verdict Against Johnson & Johnson in California Transvaginal Mesh Case

According to Reuters, yet another jury has returned a multi-million dollar award against Johnson & Johnson in a vaginal mesh lawsuit. In the latest of a series of trials, a California state jury sitting in Kern County awarded a $5.7 million verdict against Johnson & Johnson and its subsidiary Ethicon for complications with Ethicon’s Gynecare TVT […]

By

Johnson & Johnson Subsidiary McNeil PPC Inc. Pleads Guilty to Selling Children’s Medicine Containing Metal Particles

According to Law360, a unit of the healthcare giant Johnson & Johnson pleaded guilty Tuesday to a federal criminal charge for selling infants’ and children’s medicine containing metal particles. The subsidiary—McNeil PPC Inc.—must pay a $20 million criminal fine and forfeit $5 million. Unsealed court documents say metal particles, including nickel, iron, and chromium, were […]

By

Risperdal: $2.5 Million Verdict for Plaintiff in Philadelphia State Court

Philadelphia Daily News reports that a Philadelphia jury has awarded a 20 year old autistic man, Austin Pledger, $2.5 million after he developed size 46 DD breasts (a condition referred to as gynecomastia) as a young teenager after using the antipsychotic drug Risperdal. In particular, the jury found that the manufacturer, Johnson & Johnson, failed […]

By

TVM MDL Update (MDL 2187): C.R. Bard Transvaginal Mesh Litigation Moves Forward

On December 17, 2014, Judge Joseph Goodwin, the federal judge overseeing the C.R. Bard Multidistrict Litigation (MDL 2187) in West Virginia, issued an order designating sixty (60) transvaginal mesh (TVM) cases involving the manufacturer C.R. Bard as ‘Miniwave 1’ cases. Per a previous order issued by the Court on December 10, 2014, these cases will […]

By

Judge Says Transvaginal Mesh Manufacturer C.R. Bard Faces Billions in Verdicts, Bloomberg Reports

Bloomberg reports that Judge Joseph Goodwin, the federal judge overseeing the C.R. Bard Multidistrict Litigation (MDL 2187) in West Virginia, “took the unusual step of urging C.R. Bard to settle thousands of lawsuits over defective vaginal-mesh implants because juries may award billions of dollars in damages.” Judge Goodwin said during a December 9th hearing, “I […]

By

FDA Remains Undecided Regarding the Potential Ban on Power Morcellators

The Democrat & Chronicle reports that the Food and Drug Administration (FDA) held hearings more than two months ago regarding the issue of whether to ban power morcellators. However, the FDA has yet to rule on the issue and affected families are outraged about the delay. FDA spokesperson Morgan Liscinsky provided, “The FDA is considering […]

By

Xarelto® Lawsuit Update: Bayer & Johnson & Johnson Aim to Expand Uses for Xarelto

The Wall Street Journal reports that Johnson & Johnson and Bayer AG recently announced plans to launch clinical trials of Xarelto® against new diseases in order to double the number of indications and widen the market for Xarelto®, which is already poised to exceed $1 billion in sales for 2014. In particular, Yahoo! Finance reports […]

By

DePuy Executive Questioned regarding Safety Studies for DePuy Pinnacle™ Hips

Reuters reports that an executive at Johnson & Johnson’s DePuy Orthopaedics Inc. unit has testified in the first DePuy Pinnacle™ bellwether regarding the company’s assessment of safety risks associated with its Pinnacle™ hip implants. Pamela Plouhar, the DePuy executive and worldwide vice president of clinical research, was questioned about the studies DePuy performed on these […]

By

Xarelto® Lawsuit Update: Bayer/Johnson & Johnson Plan to Further Expand Indications for Xarelto®

Yahoo! Finance reports that Bayer and its partner Johnson & Johnson plan to potentially expand Xarelto®’s use for the prevention of potentially deadly blood clots in patients at risk of arterial thromboembolism. The companies plan to evaluate Xarelto® for such a new indication in three clinical studies: (1) In a global phase III study (NAVIGATE […]

By

Hysterectomy Device May Spread Undetected Cancer, New Study Finds

The Wall Street Journal reports that a surgical device used to remove uterine fibroids and during hysterectomies may spread previously undetected cancerous tissue inside the body, according to a recent study published in the Journal of the American Medical Association (JAMA). The study, conducted by Columbia University doctors, found that 1 in 368 women who […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.